Menno Kiel

Bis 2023, Global Medical Director, Hematology, F. Hoffman La Roche AG

Zürich, Schweiz

Über mich

Confident communicator with an analytical mindset and a well-developed moral compass, passionate about bringing innovative treatments to patients in need from all over the world. Uniquely skilled as physician and health economist who can leverage both his medical expertise and his knowledge on health technology assessment, outcomes research, health law, regulatory affairs and market access. Has 6+ years of medical affairs experience at the country, regional and global level; 7+ years of clinical scientific experience, and 9+ years of university-level medical education experience. Humanist, pragmatist, and sympathetic yet efficient organizer.

Fähigkeiten und Kenntnisse

Consulting
Strategy Development
Early Access Programs
Medical Affairs Management
Hematology
Oncology
CAR-T
CD20xCD3 bi-mAbs
Regulatory Affairs
Health economics
Market Access

Werdegang

Berufserfahrung von Menno Kiel

  • Bis heute 9 Monate, seit Sep. 2023

    Freelance Consultant

    GLG - Gerson Lehrman Group
  • 3 Jahre und 1 Monat, Juli 2020 - Juli 2023

    Global Medical Director, Hematology

    F. Hoffman La Roche AG

    Medical Lead, Pre-Approval Access / Compassionate Use Programs of the CD20xCD3 bispecifics glofitamab (Columvi) and mosunetuzumab (Lunsumio). Single PoC for senior leadership, drug safety, clinical science, logistics & supply and country affiliates.

  • 1 Jahr, Juli 2019 - Juni 2020

    Global Study Responsible Physician

    Actelion Pharmaceuticals Ltd

    Global daily medical management of the “A DUE” clinical trial (NCT03904693) on the effects of a fixed-dose combination of macitentan & tadalafil in pulmonary arterial hypertension (PAH).

  • 6 Monate, Dez. 2018 - Mai 2019

    Regional Medical Advisor

    Janssen-Cilag GmbH, Johnson & Johnson

    Medical Advisor for ibrutinib (Imbruvica) and daratumumab (Darzalex) for the Dutch language area of the Benelux

  • 1 Jahr, Okt. 2017 - Sep. 2018

    Country Medical Advisor

    AstraZeneca Pharmaceuticals, The Netherlands

    Local medical expert for AZ's women’s cancer products: olaparib (Lynparza), fulvestrant (Faslodex), goserelin (Zoladex) and anastrozole (Arimidex)

  • 9 Jahre und 8 Monate, Dez. 2007 - Juli 2017

    Program Director & Senior Medical Lecturer

    Rotterdam University of Applied Sciences

    Daily leadership of the physician assistant master program (MPA), medical teaching responsibilities.

  • 8 Jahre, Jan. 2009 - Dez. 2016

    Clinical Scientist & Trial Physician

    Erasmus University Medical Center

    Co-leadership & daily management of the AIRFORCE-trial: NTR-NL25370.078.09, an academic phase III multi-center RCT on the costs & effects of subcutaneous allergen immunotherapy in adult allergic rhinitis.

  • 1 Jahr, Nov. 2006 - Okt. 2007

    Junior Resident Physician Obstetrics & Gynecology

    Zaans Medical Centrum

    Tending to the medical needs of pregnant and non-pregnant women at the departments of obstetrics, gynecology & fertility medicine.

Ausbildung von Menno Kiel

  • 3 Jahre, Sep. 2008 - Aug. 2011

    Health Economics, Policy & Law (HEPL)

    Erasmus University Rotterdam

  • 6 Jahre und 11 Monate, Sep. 1999 - Juli 2006

    Human medicine

    University of Amsterdam

Sprachen

  • Niederländisch

    Muttersprache

  • Englisch

    Fließend

  • Deutsch

    Gut

  • Französisch

    Grundlagen

Interessen

Cycling
Photography
Reading
Electronic music
Classical music
Jazz music
Diving

21 Mio. XING Mitglieder, von A bis Z